# Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy

> **NCT03649529** · EARLY_PHASE1 · UNKNOWN · sponsor: **Timmune Biotech Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** GPA-TriMAR-T

## Key facts

- **NCT ID:** NCT03649529
- **Lead sponsor:** Timmune Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-27
- **Primary completion:** 2021-09-15
- **Final completion:** 2022-01-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2019-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649529, "Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03649529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*